FDA extends decision date for Sage’s postpartum depression injection

Sage Therapeutics (NSDQ:SAGE) said today that the FDA extended its decision date for Sage’s Zulresso brexanolone injection to March 19, 2019.

The U.S. regulatory agency was previously slated to decide whether or not to approve the drug as a treatment for postpartum depression by Dec. 19.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA extends decision date for Sage’s postpartum depression injection appeared first on MassDevice.